코스피
3,202.03
(26.26
0.83%)
코스닥
799.37
(1.10
0.14%)
  • 비트코인

    165,700,000(3.03%)

  • 이더리움

    4,167,000(3.07%)

  • 리플

    4,051(5.28%)

  • 비트코인 캐시

    701,500(2.11%)

  • 이오스

    896(-0.45%)

  • 비트코인 골드

    1,313(-763.82%)

  • 퀀텀

    3,170(1.38%)

  • 이더리움 클래식

    25,880(3.69%)

  • 비트코인

    165,700,000(3.03%)

버튼
가상화폐 시세 관련기사 보기
  • 비트코인

    165,700,000(3.03%)

  • 이더리움

    4,167,000(3.07%)

  • 리플

    4,051(5.28%)

  • 비트코인 캐시

    701,500(2.11%)

  • 이오스

    896(-0.45%)

  • 비트코인 골드

    1,313(-763.82%)

  • 퀀텀

    3,170(1.38%)

  • 이더리움 클래식

    25,880(3.69%)

정보제공 : 빗썸 닫기

[PRNewswire] More People Treated With Once-weekly Semaglutide Achieved

입력 2017-09-12 20:15  

[PRNewswire] More People Treated With Once-weekly Semaglutide Achieved

Reductions in Both Glucose and Weight vs. Comparator Treatments

-- Poster # 820



[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.



(LISBON, Portugal, September 12, 2017 PRNewswire=연합뉴스) A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included placebo, sitagliptin, insulin glargine U100 or exenatide extended release (ER). The analysis was presented today at the 53rd Annual Meeting of the European Association For The Study Of Diabetes.[1]



"As a physician, helping patients with type 2 diabetes achieve glycaemic and weight loss targets can be challenging," said Dr Helena Rodbard, SUSTAIN 5 investigator and medical director at Endocrine and Metabolic Consultants, Rockville, Maryland. "The meaningful reductions demonstrated with semaglutide in both glucose and body weight are encouraging, as more treatment strategies are needed to help meet this challenge."



Significantly more people treated with once-weekly semaglutide achieved the clinically meaningful composite endpoint of ≥1% HbA1c reduction and ≥5% weight loss with 0.5 mg (25-35%) and 1.0 mg (38-56%) semaglutide vs. all comparators (2-13%; p<0.0001) in SUSTAIN 1-5.[1]<br>


In addition, more people achieved the composite endpoint with once-weekly semaglutide 1.0 mg compared with semaglutide 0.5 mg (p<0.0001 for SUSTAIN 2, 4 and 5; p=0.17 for SUSTAIN 1).[1]<br>


In this post-hoc analysis, semaglutide was well tolerated, with a safety profile similar to that of other glucagon-like peptide-1 receptor agonists. The most common adverse event with semaglutide was nausea. In SUSTAIN 1-4, severe or blood glucose confirmed symptomatic hypoglycaemia events were fewer or similar with once-weekly semaglutide vs. comparators. In SUSTAIN 5, on a background of basal insulin, more events were observed with once-weekly semaglutide than with placebo.[1]



About semaglutide

Semaglutide is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake.[2]-[5] Once-weekly semaglutide is currently under review by seven regulatory agencies, including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).



About the SUSTAIN clinical trial programme

SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical trial programme for semaglutide, administered once weekly, that comprises seven phase 3a global clinical trials and a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes.



Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries. For more information, visit novonordisk.com, Facebook [http://www.facebook.com/novonordisk ], Twitter [http://www.twitter.com/novonordisk ], LinkedIn [http://www.linkedin.com/company/novo-nordisk ], YouTube [http://www.youtube.com/novonordisk ]



Novo Nordisk A/S

Corporate Affairs

Novo Alle

2880 Bagsværd


Denmark

Telephone: +45-4444-8888

Internet: http://www.novonordisk.com

CVR no: 24 25 67 90



References



1. Rodbard H, Bellary S, Hramiak I, et al. Responder analysis of subjects achieving HbA1c ≥1% and weight loss ≥5% across SUSTAIN 1-5 clinical trials. Poster 802. 53rd Annual Meeting of the European Association For The Study Of Diabetes (EASD), Lisbon, Portugal; 11-15 September 2017.



2. Korsatko A, Brunner M, Sach-Friedl S, et al. Effect of once-weekly semaglutide on the counter-regulatory response to hypoglycaemia in subjects with type 2 diabetes. Abstract 764. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.



3. Kapitza C, Dahl K, Jaconsen B, et al. The effects of once-weekly semaglutide on ß-cell function in subjects with type 2 diabetes. Abstract 754. 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Munich, Germany; 12-16 September 2016.



4. Blundell J, Finlayson G, Axelsen MB, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017; ePub ahead of print. DOI: 10.1111/dom.12932.



5. Saad H, Hjersted J, Axelsen MB, et al. Semaglutide improves postprandial glucose and lipid metabolism and delays first-hour gastric emptying in subjects with obesity. Canadian Journal of Diabetes. 2016; 40:S34-S35.



Further information

Media:

Katrine Sperling

+45-4442-6718

krsp@novonordisk.com



Asa Josefsson

+45-3079-7708

aajf@novonordisk.com




Investors:

Peter Hugreffe Ankersen

+45-3075-9085

phak@novonordisk.com



Hanna Ogren

+45-3079-8519

haoe@novonordisk.com



Anders Mikkelsen

+45-3079-4461

armk@novonordisk.com



Christina Jensen

+45-3079-3009

cnje@novonordisk.com



Kasper Veje (US)

+1-609-235-8567

kpvj@novonordisk.com



Source: Novo Nordisk

(끝)





<저작권자(c) 연합뉴스, 무단 전재-재배포 금지>

관련뉴스

랭킹뉴스 더보기

가상화폐 시세 기사 보기 +

    • 비트코인

      165,700,000(3.03%)

    • 이더리움

      4,167,000(3.07%)

    • 리플

      4,051(5.28%)

    • 비트코인 캐시

      701,500(2.11%)

    • 이오스

      896(-0.45%)

    • 비트코인 골드

      1,313(-763.82%)

정보제공 : 빗썸

온라인에서 만나는 '한경TV LIVE'
  • 한국경제TV 24시간 LIVE
  • 굿모닝 작전 관세 악재 속 2분기 실적 시즌 돌입... 희비 엇갈릴 업종은?
  • 오늘장 뭐사지? 엔비디아 4조 달러 터치 K-반도체 영향은? ㅣ 오늘장 뭐사지? | 강준혁 250710
  • 주식 콘서트 - 변동성 장세 단기 핵심 유망주 大공개! | 이동근
  • 미국증시 오프닝 라이브 [LIVE] 트럼프 “나머지 국가에 15~20% 관세” | 테슬라, 인도 공식 진출 | 니드햄 “넷플릭스, 직원 생산성 가장 높아” | 미국증시 오프닝 라이브ㅣ07/11

한국경제TV

24시간 LIVE 채팅참여

top
  • 마이핀
  • 와우캐시
  • 고객센터
  • 페이스 북
  • 유튜브
  • 카카오페이지

마이핀

와우캐시

와우넷에서 실제 현금과
동일하게 사용되는 사이버머니
캐시충전
서비스 상품
월정액 서비스
GOLD 한국경제 TV 실시간 방송
GOLD PLUS 골드서비스 + VOD 주식강좌
파트너 방송 파트너방송 + 녹화방송 + 회원전용게시판
+SMS증권정보 + 골드플러스 서비스

고객센터

강연회·행사 더보기

7일간 등록된 일정이 없습니다.

이벤트

7일간 등록된 일정이 없습니다.

공지사항 더보기

open
핀(구독)!
광고삭제